Φορτώνει......
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cochrane Database Syst Rev |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley & Sons, Ltd
2021
|
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092423/ https://ncbi.nlm.nih.gov/pubmed/33930176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub3 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|